Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

The merits of FDDNP-PET imaging in Alzheimer's disease.

Shin J, Kepe V, Barrio JR, Small GW.

J Alzheimers Dis. 2011;26 Suppl 3:135-45. doi: 10.3233/JAD-2011-0008. Review.

PMID:
21971458
2.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.

PMID:
20385246
3.

Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease.

Shin J, Lee SY, Kim SH, Kim YB, Cho SJ.

Neuroimage. 2008 Nov 1;43(2):236-44. doi: 10.1016/j.neuroimage.2008.07.022. Epub 2008 Jul 23.

PMID:
18694837
4.

PET of brain amyloid and tau in mild cognitive impairment.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR.

N Engl J Med. 2006 Dec 21;355(25):2652-63.

5.

Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease.

Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, Huang SC, Barrio JR, Ercoli LM, Siddarth P, Satyamurthy N, Liu J, Toga AW, Bookheimer SY, Small GW, Thompson PM.

Neurobiol Aging. 2010 Oct;31(10):1669-78. doi: 10.1016/j.neurobiolaging.2008.09.012. Epub 2008 Nov 11.

6.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
7.

2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations.

Shin J, Lee SY.

Am J Geriatr Psychiatry. 2010 Feb;18(2):187; author reply 188. doi: 10.1097/JGP.0b013e3181c29446. No abstract available.

PMID:
20104075
8.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.

9.

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.

Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ, Libri V, Lockhart A.

J Neurochem. 2009 Apr;109(2):623-30. doi: 10.1111/j.1471-4159.2009.05996.x. Epub 2009 Feb 13.

10.

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR.

Am J Geriatr Psychiatry. 2002 Jan-Feb;10(1):24-35.

PMID:
11790632
11.

Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults.

Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, Burggren AC, Bookheimer SY, Huang SC, Barrio JR, Small GW.

Am J Geriatr Psychiatry. 2009 Jun;17(6):493-502.

13.

Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL.

Brain. 2014 Jun;137(Pt 6):1762-71. doi: 10.1093/brain/awu064. Epub 2014 Mar 27.

PMID:
24681664
14.

Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans.

Wardak M, Wong KP, Shao W, Dahlbom M, Kepe V, Satyamurthy N, Small GW, Barrio JR, Huang SC.

J Nucl Med. 2010 Feb;51(2):210-8. doi: 10.2967/jnumed.109.063701. Epub 2010 Jan 15.

15.

Visualizing pathology deposits in the living brain of patients with Alzheimer's disease.

Kepe V, Huang SC, Small GW, Satyamurthy N, Barrio JR.

Methods Enzymol. 2006;412:144-60. Review.

PMID:
17046657
16.

In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.

Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O'Brien JT.

Ageing Res Rev. 2017 Jul;36:50-63. doi: 10.1016/j.arr.2017.03.002. Epub 2017 Mar 15. Review.

PMID:
28315409
17.

Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR.

J Neurosci. 2001 Dec 15;21(24):RC189.

19.
20.

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.

Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, Lavretsky H, Thompson PM, Cole GM, Huang SC, Phelps ME, Bookheimer SY, Barrio JR.

Arch Gen Psychiatry. 2009 Jan;66(1):81-7. doi: 10.1001/archgenpsychiatry.2008.516.

Supplemental Content

Support Center